Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 22 for “"CYP4F2"”.
-
Frecuencias alélicas y genotípicas de polimorfismos en los genes cyp2c9, vkorc1 y cyp4f2 en pacientes colombianos anticoagulados con warfarina
The oral anticoagulant warfarin is the most used worldwide, formulated for the treatment and prevention of thrombotic diseases, its narrow therapeutic index and the wide variability between patients make it difficult dosage, so it is necessary to determine the frequencies of polymorphisms in genes …
-
Precision Approaches for Assessing Complex Pharmacogenomic Traits in Vitamin K Metabolism
… particular interest for this dissertation is the CYP4F2*3 coding variant, which has been shown to decrease vitamin K (VK) metabolic clearance in vitro and is associated with altered pharmacodynamic effects of coumarin based anticoagulant drugs (e.g., Warfarin) in vivo. On average, CYP4F2*3 …
-
The Cytochrome P450 Family 4 Enzymes: Focus on Inhibition by Formamdioxime Analogues and Metabolism of Vitamin K
… of competitive inhibitors that are selective for CYP4F2 and CYP4F3B and do not inhibit CYP4A11. These CYP4 enzymes are principally responsible for biosynthesis of the signaling eicosanoid, 20-HETE. Additionally, HET0016 was established as a mechanism-based inhibitor of CYP4A11, but not of other …
-
Farmacogenética da varfarina : proposta de um algoritmo para a predição de dose
… da varfarina, respectivamente. A enzima CYP4F2, envolvida na metabolização de vitamina K, atua de forma indireta na farmacodinâmica do medicamento. O fator II é um fator de coagulação dependente de carboxilação, sendo sua funcionalidade dependente da atuação da varfarina. Polimorfismos …
-
Genetic and Environmental Factors Affecting Hemostasis in Yup'ik People
… genetic variants of the vitamin K hydroxylases, CYP4F2 and CYP4F11, as well as VKORC1, which catalyzes the recycling of the vitamin in the liver. Additionally, we measured the vitamin K content of tundra greens that are part of the traditional Yup'ik diet to determine if these foods are a …
-
The Effect of Gene-Obesity and Gene-Care Setting Interactions on Risk of Major Bleeding Events in Warfarin Users
… significant interaction was found between CYP4F2 x obesity, however, the p-value of 0.049 would not hold its statistical significance to Bonferroni correction for multiple comparisons. No statistically significant interaction was found between CYP2C9/VKORC1 x care setting or between CYP4F2 …
-
The Role Of Vitamin E Hydroxylases In Vitamin E Metabolism And Status
… pathway. Cytochrome P450 4F2 (CYP4F2) is the only known human enzyme shown to display TOH-[omega]-hydroxylase activity. In an effort to investigate the role of TOH-[omega]-hydroxylase activity in vitamin E metabolism and status, the functional murine ortholog of CYP4F2 was …
-
ENZYMATIC REGULATION OF VITAMIN E STATUS: IDENTIFICATION AND CHARACTERIZATION OF THE NOVEL TOCOPHEROL-OMEGA-HYDROXYLASE PATHWAY OF VITAMIN E CATABOLISM
… enzyme activity led to the elucidation of CYP4F2 as the major P450 involved in the initial omega-hydroxylation reaction. Substrate-specificity of this enzyme was high, with activity toward gamma-tocopherol being 10-fold greater than toward alpha-tocopherol. Sesamin, known to raise plasma …
-
Impact of Warfarin Pharmacogene Variation on Drug Metabolism and Pharmacological Response in Alaska Native and American Indian Populations
… factors. While variation in VKORC1, CYP2C9, CYP4F2 and GGCX genes have been associated with the warfarin dose required to achieve a therapeutic anticoagulation response, these findings are based largely on variant alleles and their frequencies found in populations largely of European descent, …
-
Genetic and environmental associations with disease risk and drug response in Alaska Native people, and a responsive justice approach to reconciling statistical and ethical research demands.
… novel and known variation in CYP2C9, VKORC1, CYP4F2, CYP4F11, and GGCX, 5 genes known to affect warfarin disposition and response, in 350 Yup’ik people and 365 customer-owners of Southcentral Foundation. Through resequencing and targeted genotyping, we identified two common novel variants M1L …
-
Supplementation to Improve Anticoagulation Control with Low Dose Vitamin K as an Adjuvant to Warfarin Therapy: A Double-blind, Placebo-controlled Randomized Controlled Trial
… warfarin and Vitamin K metabolism [VKORC1, CYP4F2, CYP2C9] had on anticoagulation control and intervention effectiveness. A total of N=54 patients were enrolled in the study over 15 months [January 2009 to June 2010]. Change score analysis and multivariate linear regression modelling of …
-
The pharmacogenomics of warfarin safety and effectiveness in children
… assay . Associations between CYP2C9/VKORC1/ CYP4F2 genotypes and therapeutic dose, time to therapeutic INR /time to over - anticoagulation , and incidence of adverse drug reactions were analyzed . Additional variants in genes involved in vitamin K and coagulation pathways were tested for an …
-
Determination of Absolute Protein Content of Hepatic CYP4F Enzymes in Human Liver Microsomes Using LC/MS/MS Methodology and Comparison with Immunoquantification and Enzyme Activity
… donor HLM was determined by LC/MS/MS for CYP4F2, CYP4F3B, CYP3A, CYP3A4, and CYP3A5. The contribution of CYP4F enzymes to the overall hepatic CYP "pie" was also determined. The observed enzyme protein values were then correlated with immunoquantified protein content and enzyme activity. …
-
Network-guided genome-wide studies reveal a complex genetic architecture of warfarin resistance in the Norway rat (Rattus norvegicus)
… window with several genes VKORC1, CYP2C9, CYP4F2 established as biomarkers predicting warfarin dose in humans, suggesting a complex genetic architecture of warfarin resistance in rodents. In my thesis I performed network-guided genomic association studies (NetGWAS) and gene expression …
-
Comparative Effectiveness Approaches to Evaluate Pharmacogenomic Technology
… I demonstrate the first association between CYP4F2 variants and decreased risk of major bleeding, and provided exploratory evidence suggesting differential CYP2C9 variant bleeding risk based on geographic setting. In the ERCC1 VOI analysis, I demonstrate that a trial is expected to cost $30m, …
-
Pharmacogenetic, clinical and demographic factors in the management of warfarin therapy.
… for SNP analysis of the VKORC1, CYP2C9 and CYP4F2 genes. Group 3 subjects (n=20) comprised of pre-warfarinised patients who provided the same data as in group 2. In addition, venous blood samples were obtained for the measurement of the baseline levels of the vitamin K dependent coagulation …
-
IMPORTANCE OF SUPPLYING DAIRY COWS WITH ESSENTIAL FATTY ACIDS (EFA) AND CONJUGATED LINOLEIC ACIDS (CLA) DURING THE TRANSITION PERIOD ON METABOLISM AND HEALTH
… specific CYP enzymes comprising CYP51A1, CYP1A1, CYP4F2, and CYP4V2. A total of 241 unique proteins was identified in the plasma, in which a cluster of apolipoproteins (APO) containing APOC3, APOA1, APOA4, and APOC4 was increased in response to EFA+CLA according to the stage of lactation. …
-
Pharmacogenetic Investigations Using Community-Based Participatory Research to Address Health Disparities in Minnesota Hmong
… frequencies of CYP2C19, CYP2C9, VKORC1, and CYP4F2 were higher in the Hmong relative to Caucasian. Disease risk allele frequencies of hyperuricemia and gout associated genes such as SLC2A9, SLC17A1, SLC22A11, SLC22A12, ABCG2, PDZK1, were also higher in the Hmong than Caucasian and …
-
Toward Individualized Medicine in Understudied Populations using Personal Genome and Microbiome
… include CYP2C9*3A, CYP2C19*2, CYP2C19*3, CYP4F2*3, and SLCO1B1*5. Additionally, a higher portion of Hmong participants (50%) are predicted to have an intermediate metabolizer phenotype for CYP2D6 compared to other East Asians which range between 27%-44%. The differences significantly …
-
Mass Spectrometry-Based Quantitative Proteomics for Drug-Metabolizing Enzymes
… the screening of anticancer prodrugs. Lastly, CYP4F2-specific targeted quantification was used to confirm the mechanism underlying a potential drug-drug interaction between warfarin and lovastatin. UPLC-MRM-based targeted proteomic techniques have many advantages, but the cost and time required …
Page 1 of 2